Fundraising Fox
Dorian Therapeutics
acquired by Altos LabsYC S18San Francisco, US · Founded 2018 · 8 employees · 3 known investors
Find your way into Dorian Therapeutics
Sign up to see every warm intro you have to Dorian Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dorian Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.
Founders & leadership· Y Combinator alumni (S18)
Dorian Therapeutics was founded in 2018 by Maddalena Adorno and Benedetta di Robilant.
MA
Maddalena AdornoCo-Founder and CEOMaddalena Adorno is a researcher with background in stem cells, oncology, and aging biology who has published in peer-reviewed journals including Nature, Science, and Cell, and holds three international patents in cancer and degenerative diseases. She founded Dorian Therapeutics, a biotechnology company developing senoblockers to target aging-related cellular mechanisms, which was later acquired by Altos Labs.
Investors · 3
Related companies · 4
SFA TherapeuticsSFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
dNovodNovo develops direct reprogramming technology to convert skin, blood, or fat cells into new stem cells, targeting age-related stem cell depletion. The company aims to address aging through cellular regeneration for consumers.
Rejuvenation Technologies Inc.Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
Eat BlueprintEat Blueprint prepares meals based on longevity-focused nutritional protocols, using organic and locally-sourced ingredients while excluding gluten and seed oils.
Companies working in the same space as Dorian Therapeutics.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $452.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $335.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Legal entities · 1
corporate structureDorian Therapeutics, Inc.
In the news
Frequently asked questions
- What does Dorian Therapeutics do?
- Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.
- Who founded Dorian Therapeutics?
- Dorian Therapeutics was founded by Maddalena Adorno, Benedetta di Robilant in 2018.
- Who are Dorian Therapeutics's investors?
- Dorian Therapeutics's investors include Blumberg Capital, StartX, Y Combinator.
- Who acquired Dorian Therapeutics?
- Dorian Therapeutics was acquired by Altos Labs.
- Where is Dorian Therapeutics headquartered?
- Dorian Therapeutics is headquartered in San Francisco, US.